Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

The choice of first-line Chronic Myelogenous Leukemia treatment

(2015) Carmen Fava et al.   ANNALS OF HEMATOLOGY

RETRACTED ARTICLE: ABCB1 (1199G>A) polymorphism regulates the efficacy of docetaxel and imatinib mesylate in HEK293 recombinant cell lines

(2015) Rui Peng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib

(2015) Yanhua Yue et al.   Hematology

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

(2015) Sara Redaelli et al.   Journal of Hematology & Oncology

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

(2015) L Lu et al.   LEUKEMIA

Polycomb genes are associated with response to imatinib in chronic myeloid leukemia

(2015) Francesco Crea et al.   Epigenomics

High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients

(2015) Marc Delord et al.   Oncotarget

How I treat newly diagnosed chronic myeloid leukemia in 2015

(2014) Carlo Gambacorti-Passerini et al.   AMERICAN JOURNAL OF HEMATOLOGY

Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients

(2014) Anthony Au et al.   BIOMEDICINE & PHARMACOTHERAPY

Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?

(2014) M. V. Tzvetkov et al.   BLOOD

Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells

(2014) Petr Kosztyu et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies

(2014) Zhi-Xin Wang et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia

(2014) Jacob Vine et al.   LEUKEMIA & LYMPHOMA

ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate

(2014) Mohamed A. M. Ali et al.   MEDICAL ONCOLOGY

Nilotinib Enhances the Efficacy of Conventional Chemotherapeutic Drugs in CD34+CD38− Stem Cells and ABC Transporter Overexpressing Leukemia Cells

(2014) Fang Wang et al.   MOLECULES

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

(2014) A Di Paolo et al.   PHARMACOGENOMICS JOURNAL

ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib

(2014) DOUGLAS VIVONA et al.   Oncology Letters

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

A common novel splice variant ofSLC22A1(OCT1)is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia

(2013) Jacob Grinfeld et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)

(2013) A. T. Nies et al.   CLINICAL CANCER RESEARCH

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

(2013) E. I. Zimmerman et al.   CLINICAL CANCER RESEARCH

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11–12, 2013

(2013) Massimo Breccia et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

(2013) D. K. Hiwase et al.   HAEMATOLOGICA

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

(2013) Y. Shinohara et al.   HAEMATOLOGICA

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects

(2013) Narayana I. Narasimhan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome

(2013) S Bouchet et al.   LEUKEMIA

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

(2012) S. J. Seong et al.   ANNALS OF ONCOLOGY

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

(2012) A. Giannoudis et al.   BLOOD

Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models

(2012) Amit K. Tiwari et al.   CANCER LETTERS

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

(2012) S. Angelini et al.   HAEMATOLOGICA

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

(2012) R A Larson et al.   LEUKEMIA

Degree of kinase inhibition achievedin vitroby imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2

(2012) Laura N. Eadie et al.   LEUKEMIA & LYMPHOMA

The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2

(2012) R. Sen et al.   MOLECULAR CANCER THERAPEUTICS

Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells?

(2012) Petr Kosztyu et al.   PHARMACOLOGICAL RESEARCH

SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemia

(2012) Onkar Singh et al.   PLoS One

Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells

(2011) Petr Mlejnek et al.   ANNALS OF HEMATOLOGY

Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2)

(2011) Ichiro Ieiri   Drug Metabolism and Pharmacokinetics

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins

(2011) T. Minematsu et al.   MOLECULAR CANCER THERAPEUTICS

An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics

(2011) S J Wolf et al.   PHARMACOGENOMICS JOURNAL

CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity

(2010) Henrik Gréen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Metabolism considerations for kinase inhibitors in cancer treatment

(2010) Derek R Duckett et al.   Expert Opinion on Drug Metabolism & Toxicology

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

(2010) Deborah L. White et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

(2010) Chiaki Tanaka et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects

(2010) Richat Abbas et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

(2010) Naoto Takahashi et al.   JOURNAL OF HUMAN GENETICS

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1

(2010) D L White et al.   LEUKEMIA

Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia

(2010) Ling-Na Ni et al.   MEDICAL ONCOLOGY

Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

(2009) Amit K. Tiwari et al.   BIOCHEMICAL PHARMACOLOGY

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

(2009) J. S. Lagas et al.   CLINICAL CANCER RESEARCH

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib

(2009) Sophia Hatziieremia et al.   EXPERIMENTAL HEMATOLOGY

Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance

(2009) Wenyong W. Zhang et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

(2009) A Davies et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs

(2009) Sarah Shugarts et al.   PHARMACEUTICAL RESEARCH

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

(2008) A. Giannoudis et al.   BLOOD

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

(2008) Divya Menon-Andersen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Interaction of Imatinib with Human Organic Ion Carriers

(2008) S. Hu et al.   CLINICAL CANCER RESEARCH

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

(2008) D. K. Hiwase et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

(2008) A. Petain et al.   CLINICAL CANCER RESEARCH